RxDoctor Payments Data

Chad Hammett, MD

General Practice · Beaumont, TXNPI 1083731756

Payments from drug & device makers

$7,285in general payments, 2019–2025

Across 445 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bayer$547
  • GSK$542
  • Pfizer$359
  • Sunovion Pharmaceuticals Inc.$338
  • Amarin Pharma, Inc.$307
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$7,254100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,285 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$285,581
Medicare patients
584
Services billed
9,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban616$294,629
OzempicSemaglutide138$150,560
GemtesaVibegron473$129,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$95,352
TrulicityDulaglutide50$74,342
FarxigaDapagliflozin Propanediol132$72,686
MounjaroTirzepatide55$67,825
XareltoRivaroxaban151$67,370
JanuviaSitagliptin Phosphate84$58,971
NuplazidPimavanserin Tartrate20$49,712
MyrbetriqMirabegron117$45,332
EntrestoSacubitril/Valsartan83$34,439
JardianceEmpagliflozin53$29,432
Tresiba Flextouch U-200Insulin Degludec54$28,462
LinzessLinaclotide40$24,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$359$294,629616 claims
Novo NordiskOzempic, Wegovy, Rybelsus, Levemir$246$201,817222 claims
Lilly USA, LLCTrulicity, Mounjaro$157$142,167105 claims
Sumitomo Pharma America, Inc.Gemtesa$63$129,749473 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$221$109,469199 claims
GSKTrelegy Ellipta, Breo Ellipta$542$105,858131 claims
Johnson & JohnsonXarelto$34$67,370151 claims
MerckJanuvia$100$58,97184 claims
AbbVieLinzess, Creon$1,815$47,18254 claims
Astellas Pharma US IncMyrbetriq$27$45,332117 claims
Boehringer IngelheimJardiance, Tradjenta$57$41,25882 claims
NovartisEntresto$179$34,43983 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.

Other general practice in Beaumont

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →